Boston Scientific Corp will reserve most of the $1 billion (€760 million) in free cash it expects to generate in 2012 for acquisitions, with plans to use 25% to buy back shares, chief financial officer Jeff Capello said.

BOSTON Scientific Corp, the second-biggest heart- device maker by revenue, said third-quarter profit declined 25% as demand fell for its defibrillators and pacemakers used to regulate the heart.